Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03)

被引：6

作者：

Roussel, Murielle ^{[1
,2
]}

Hebraud, Benjamin ^{[1
,2
]}

Hulin, Cyrille ^{[3
]}

Leleu, Xavier ^{[4
]}

Facon, Thierry ^{[5
]}

Boyle, Eileen ^{[6
]}

Touzeau, Cyrille ^{[7
]}

Pegourie, Brigitte ^{[8
]}

Perrot, Aurore ^{[9
,10
]}

Stoppa, Anne-Marie ^{[11
]}

Marolleau, Jean-Pierre ^{[12
]}

Moreau, Philippe ^{[13
]}

Avet-Loiseau, Herve ^{[14
]}

Devlamynck, Laure ^{[15
]}

Lauwers-Cances, Valerie ^{[15
]}

Attal, Michel ^{[1
,2
]}

机构：

[1] Inst Univ Canc, Toulouse, France

[2] Univ Hosp, Toulouse, France

[3] Hop Haut Leveque, Dept Hematol, Pessac, France

[4] CHU Poitiers, Serv Hematol & Therapie Cellulaire, Poitiers, France

[5] Hop Claude Huriez, Hosp Huriez, Serv Malad Sang, Lille, France

[6] CHU Lille, Dept Hematol, Lille, France

[7] CHU Nantes, Nantes, France

[8] Ctr Hosp Univ CHU Grenoble, Dept Hematol, Grenoble, France

[9] Hop Brabois, Vandoeuvre Les Nancy, France

[10] Univ Hosp, Dept Hematol, Vandoeuvre Les Nancy, France

[11] Inst Paoli Calmettes, Marseille, France

[12] Amiens Univ Hosp, Dept Hematol, Amiens, France

[13] Univ Hosp Hotel Dieu, Clin Hematol, Nantes, France

[14] IUC T Oncopole, Unite Genom Myelome, Toulouse, France

[15] CHU Toulouse, Serv Epidemiol, USMR, Toulouse, France

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-123184

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3159

引用

页数：4

共 36 条

[1] Twice-weekly induction with ixazomib-lenalidomide-dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant-eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014-03
Perrot, Aurore
Roussel, Murielle
Lauwers-Cances, Valerie
Hulin, Cyrille
Leleu, Xavier
Touzeau, Cyrille
Facon, Thierry
Mariette, Clara
Schiano, Jean-Marc
Gay, Julie
Montes, Lydia
Ranta, Dana
Huguet, Amandine
Wuilleme, Soraya
Dejoie, Thomas
Devlamynck, Laure
Corre, Jill
Avet-Loiseau, Herve
Moreau, Philippe
Attal, Michel
BRITISH JOURNAL OF HAEMATOLOGY, 2024,
[2] Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyeLome (IFM)
Moreau, Philippe
Hulin, Cyrille
Caillot, Denis
Marit, Gerald
Perrot, Aurore
Garderet, Laurent
Facon, Thierry
Benboubker, Lotfi
Karlin, Lionel
Tiab, Mourad
Arnulf, Bertrand
Fermand, Jean-Paul
Leleu, Xavier
Touzeau, Cyrille
Roussel, Murielle
Planche, Lucie
Minvielle, Stephane
Bene, Marie-Christine
Avet-Loiseau, Herve
Dejoie, Thomas
Attal, Michel
BLOOD, 2016, 128 (22)
[3] Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation ( ASCT) Followed By Ixazomib Maintenance Is a Safe and Effective Strategy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyeLome (IFM)
Moreau, Philippe
Hulin, Cyrille
Caillot, Denis
Marit, Gerald
Perrot, Aurore
Garderet, Laurent
Facon, Thierry
Benboubker, Lofti
Karlin, Lionel
Tiab, Mourad
Arnulf, Bertrand
Leleu, Xavier
Touzeau, Cyrille
Roussel, Murielle
Planche, Lucie
Avet-Loiseau, Herve
Dejoie, Thomas
Attal, Michel
BLOOD, 2017, 130
[4] Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myelome (IFM)
Perrot, Aurore
Lauwers-Cances, Valerie
Touzeau, Cyrille
Decaux, Olivier
Hulin, Cyrille
Macro, Magaret
Stoppa, Anne-Marie
Chretien, Marie Lorraine
Karlin, Lionel
Mariette, Clara
Jacquet, Caroline
Roussel, Murielle
Guillemot, Coralie
Devlamynck, Laure
Avet-Loiseau, Herve
Moreau, Philippe
Attal, Michel
BLOOD, 2021, 138
[5] Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyeLome (IFM) Krd Phase II Study
Roussel, Murielle
Lauwers-Cances, Valerie
Robillard, Nelly
Belhadj, Karim
Facon, Thierry
Garderet, Laurent
Escoffre, Martine
Pegourie, Brigitte
Benboubker, Lotfi
Caillot, Denis
Fohrer, Cecile
Moreau, Philippe
Leleu, Xavier
Avet-Loiseau, Herve
Attal, Michel
BLOOD, 2016, 128 (22)
[6] Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myelome
Roussel, Murielle
Lauwers-Cances, Valerie
Robillard, Nelly
Hulin, Cyrille
Leleu, Xavier
Benboubker, Lotfi
Marit, Gerald
Moreau, Philippe
Pegourie, Brigitte
Caillot, Denis
Fruchart, Christophe
Stoppa, Anne-Marie
Gentil, Catherine
Wuilleme, Soraya
Huynh, Anne
Hebraud, Benjamin
Corre, Jill
Chretien, Marie-Lorraine
Facon, Thierry
Avet-Loiseau, Herve
Attal, Michel
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) : 2712 - +
[7] A prospective phase 2 study to assess minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients
Silvennoinen, Raija
Waage, Anders
Peceliunas, Valdas
Schjesvold, Fredrik
Anttila, Pekka
Uttervall, Katarina
Saily, Marjaana
Putkonen, Mervi
Carlson, Kristina
Haukas, Einar
Sankelo, Marja
Partanen, Anu
Szatkowski, Damian
Hansson, Markus
Marttila, Anu
Svensson, Ronald
Axelsson, Per
Lauri, Birgitta
Mikkola, Maija
Karlsson, Conny
Abelsson, Johanna
Ahlstrand, Erik
Sikio, Anu
Nahi, Hareth
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S157 - S157
[8] Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial
Vij, Ravi
Nathwani, Nitya
Martin, Thomas G., III
Fiala, Mark A.
Deol, Abhinav
Buadi, Francis K.
Kaufman, Jonathan L.
Hofmeister, Craig C.
Gregory, Tara
Berdeja, Jesus G.
Chari, Ajai
Rosko, Ashley E.
BLOOD, 2018, 132
[9] Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial
Vij, Ravi
Martin, Thomas G., III
Nathwani, Nitya
Fiala, Mark A.
Gao, Feng
Deol, Abhinav
Buadi, Francis K.
Kaufman, Jonathan L.
Hofmeister, Craig C.
Gregory, Tara K.
Berdeja, Jesus G.
Chari, Ajai
Rosko, Ashley E.
BLOOD, 2019, 134
[10] Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial
Rosinol, Laura
Oriol, Albert
Rios Tamayo, Rafael
Jesus Blanchard, María
Jarque, Isidro
Bargay, Joan
Hernandez, Miguel-Teodoro
Maria Moraleda, Jose
Carrillo-Cruz, Estrella
Sureda, Anna
Martinez-Lopez, Joaquin
Krsnik, Isabel
Gonzalez Garcia, Esther
Casado, Felipe
Marti, Josep M.
Encinas, Cristina
De Arriba, Felipe
Palomera, Luis
Sampol, Antonia
Gonzalez-Montes, Yolanda
Cabezudo, Elena
Mateos, Maria-Victoria
San-Miguel, Jesus
Jose Lahuerta, Juan
Blade Creixenti, Joan
BLOOD, 2021, 138

← 1 2 3 4 →